News
6h
Zacks Investment Research on MSNCan OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?OptimizeRx OPRX kicked off 2025 with strong momentum, delivering 11% year-over-year revenue growth to $21.9 million and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results